Welcome to the Weekly Rundown where the DDN editors cover this week’s top biotech and pharma news.
Nobel prize in physiology or medicine awarded for lighting up the field of neuroscience
The 2026 Nobel Prize in Physiology or Medicine was awarded to Karl Deisseroth of Stanford University, Peter Hegemann of Humboldt University, and Georg Nagel of the University of Würzburg “for their discoveries concerning light-gated ion channels and optogenetics,” according to the press release. In the early 2000s, Hegemann and Nagel discovered the channelrhodopsin protein in a single-cell alga, which is activated by blue light. Then, in 2005, Deisseroth published work showing that inserting the channelrhodopsin gene into the brain cells of rats also activated these cells, triggering action potentials. The breakthrough offered neuroscientists an unprecedented view of the intricate and precise behavior of neural circuits. In the statement from the Nobel Assembly at Karolinska Institute, the team wrote, “The Laureates have laid the foundation of a new era in neuroscience.” – Allison Whitten
WHO guidance suggests other interventions over GLP-1 drugs in children
On Wednesday, the WHO published the first global guidelines related to treating obesity in children and adolescents. The report recommends lifestyle changes and mental health interventions over any drug usage or bariatric surgery for children up to nine years old, while those 10 years and older may consider medications only after other approaches have not worked.“The foundation of obesity care for children and adolescents is not medicine or surgery, but access to comprehensive support that enables healthy eating, physical activity and sustainable behaviour change,” said Luz María De Regil, Director of the Department of Nutrition and Food Safety at the WHO, in the press release. Currently, the FDA has approved GLP-1 medicines for adolescents 12 years and older, though there are reports that they are being prescribed off label for younger children. This is occurring while the drugs are still in clinical trials to assess the risks in children under 12, and new research shows that nearly one in six children ages 10-17 taking them were diagnosed with a nutritional deficiency during the first year of treatment. – Allison Whitten
Cerevance’s Parkinson’s drug closer to FDA submission after Phase 3 results
Cerevance’s potential first-in-class oral GPR6 inverse agonist, solengepras, could be on the path to approval. The company announced that the 150mg dose met the primary endpoint, decreasing the amount of time that the medication is not working (“OFF time”) by 0.61 hours compared to placebo, and was generally well tolerated with mild to moderate adverse events. The company also stated in the press release that they now plan to meet with the FDA to discuss moving towards an NDA. Levodopa remains the gold standard treatment, but with AbbVie’s FDA approval of tavapadon last month, treatment options are widening. Solengepras takes a different non-dopaminergic approach, instead targeting the GPR6 receptor in the striatum of the brain. “As a potential first-in-class, non-dopaminergic therapy, solengepras gives us the opportunity to evaluate what a new mechanism may offer people with Parkinson’s,” said Craig Thompson, CEO of Cerevance, in the statement. – Allison Whitten
Blood proteomics link menopause to brain aging and dementia risk
Researchers identified a blood-based proteomic signature of menopause that tracked more closely with hormone levels than age, in a Nature Medicine study of 80 staged pre-, peri- and postmenopausal women. Sixteen proteins spanning inflammatory, synaptic, metabolic and Alzheimer's disease biology were elevated postmenopause and correlated most strongly with FSH (follicle stimulating hormone) and estradiol. The signature was replicated in a separate 2,814-person UK Biobank cohort, where postmenopausal women showed broader inflammatory upregulation and accelerated aging across multiple organs, including the brain, and women with vasomotor symptoms like night sweats showed the sharpest inflammatory spikes, with CCL2 (C-C motif chemokine ligand 2) a consistent marker. Across four aging cohorts totaling nearly 12,000 women, higher menopause proteomic scores tracked with steeper cognitive decline and a 15 percent higher risk of Alzheimer's dementia over roughly 16 years, though not vascular, frontotemporal or all-cause dementia. The authors called the dementia-risk effect modest and the signal more a product of coordinated aging biology than any single protein, framing menopause as a discovery window for brain-health biomarkers rather than evidence it causes dementia. – Andrea Corona
Viatris bets 1.65 billion dollars that pain management's future is opioid-free
Viatris is acquiring Pacira BioSciences for 36.50 dollars a share, a 44.8 percent premium that values the deal at roughly 1.65 billion dollars and hands the generics giant two drugs: Exparel, the postsurgical anesthetic that has become a standard opioid alternative in operating rooms, and Zilretta, an extended-release knee injection for osteoarthritis pain. Together the two generated about 746 million dollars in revenue and 177 million dollars in adjusted EBITDA over the past year, the kind of high-margin, patent-protected cash flow Viatris needs as its legacy generics business faces continued pricing pressure. The acquisition pairs with Viatris' own fast-acting meloxicam candidate, awaiting an FDA decision in December, giving a company built on copying other companies' drugs a genuine non-opioid pain franchise. Pacira also brings PCRX-201, a Phase 2 gene therapy for knee osteoarthritis, extending the deal's value beyond near-term sales. As regulators and hospitals keep pushing opioid alternatives, owning the commercial infrastructure for non-opioid pain management may prove more durable than owning any one patent. – Andrea Corona
WHO launches global roadmap targeting preeclampsia and pregnancy hypertension
The World Health Organization and more than 140 partners launched the Global Roadmap for Hypertensive Disorders of Pregnancy, 2026–2035 and beyond, at the Society for Maternal-Fetal Medicine Global Conference, aiming to close what WHO calls a stark innovation gap: Despite hypertensive disorders complicating 10 to 15 percent of pregnancies worldwide and causing an estimated 42,000 maternal deaths and more than 500,000 stillbirths and newborn deaths annually, almost no medicines have been developed and approved specifically for preventing or treating preeclampsia or eclampsia. The roadmap sets out coordinated action across five areas, research and innovation, clinical guidance, access to medicines and diagnostics, implementation, and advocacy, building on 20 priority research questions identified at a May 2026 summit meant to redirect investment that has historically concentrated on diagnostics rather than new preventive or treatment options. For drug developers, the roadmap functions as an explicit call to fill a commercial white space that research investment has largely ignored, with WHO asking industry alongside governments, funders, and researchers to align around getting both proven interventions and future innovations to the women who need them. – Andrea Corona
